A Mother’s Gift of Life: Successful Living-Donor Kidney Transplant Restores Hope for 32 Years old Young CKD Patient from Bangladesh
HYDERABAD, India, Nov. 24, 2025 /PRNewswire/ -- In an inspiring story of…
Press Release: Sanofi and Regenerons Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the…
Clarivate Companies to Watch Report Spotlights Seven Women’s Health Startups Shaping the Future of Care
Report highlights emerging biotech innovators advancing new therapies, equity and investment across…
Fangzhou Awarded Golden Bull Award for Leadership in AI-Powered Chronic Disease Management
XIAMEN, China, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or…
Fangzhous XingJie LLM Completes Key National Filing, Setting Stage for Further AI-Driven Chronic Care Innovations
SHENZHEN, China, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or…
Berlin Heals Welcomes Dr. Eric Fain as New Board Member
Berlin Heals adds MedTech Veteran Dr. Eric Fain to Board of Directors…
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq:…
PEMF Therapy Emerges as a Leading 2025 Wellness Trend for Drug-Free Pain Relief; Grooni Earthings Pro Collection Meets Rising Demand
SHERIDAN, WY , Aug. 26, 2025 (GLOBE NEWSWIRE) -- As consumers seek…
Berlin Heals Announces Publication of Two-Year Clinical Outcomes of Cardiac Microcurrent Therapy in ESC Heart Failure
Study shows sustained improvements in heart failure symptoms and function following long-term C-MIC…
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal…